Revealed: The Small Cap Stock I'm ALL-IN On

Поделиться
HTML-код
  • Опубликовано: 7 апр 2024
  • 🧑‍🎓 Valuation Mindset Spectrum Webinar: brianferoldi.ck.page/bf48a012d0
    📈 Check out Finchat for FREE!: finchat.io/brian/
    ▼FREE INVESTING COURSES:▼
    🧑‍🎓 Financial Statements School: longtermmindset.co/fss
    🧑‍🎓 Stock Market School: longtermmindset.co/fss
    🧑‍🎓 Valuation School: longtermmindset.co/vs
    ▼FREE INVESTING TOOLS:▼
    ✅ Investing Checklist: brianferoldi.com/checklist
    ⚖️ Earnings Power Calculator: www.brianferoldi.com/ep
    ⏪ Reverse DCF Calculator: brianferoldi.com/rdcf
    ▼ FREE NEWSLETTER ▼
    📩 Join 100,000+ readers of our FREE newsletter: longtermmindset.co/
    ▼FREE ACCOUNTING EBOOK:▼
    ✅ 8 Accounting Terms Explained Simple: brianferoldi.com/accounting
    ▼RECOMMENDED RESOURCES:▼
    👍 Recommended Resources: brianferoldi.com/resources
    ▼ USEFUL EPISODES:▼
    📺 10 Steps To Build Wealth: • How to Build Wealth In...
    📺 How to use our investing checklists: • Brian Feroldi's Stock ...
    📺 Our thoughts on valuation: • Stock Valuation Lectur...
    📺 How to review earnings: • Quarterly Earnings Rep...
    📺 How to prepare for a market crash: • How To Prepare For A S...
    📺 10 investing lessons for beginners: • 10 Investing Lessons F...
    📺 How to build a portfolio - Step 1: • How to build a stock p...
    ▼ABOUT US:▼
    👨‍💼Brian Feroldi is an author (amzn.to/3JVr9Q0), investor, RUclipsr, and financial educator. He's been investing in the stock market since 2004. He's made EVERY investing mistake you can make. He now spends his time teaching others how to invest better. Brian sends a FREE weekly email called Long Term Mindset (brianferoldi.com), where he shares one investing lesson and 5 pieces of simple content that encourage readers to think and do better with their money.
    🤝Connect with Brian Feroldi:🤝
    🐦 Twitter: / brianferoldi
    🔗 Linkedin: / brianferoldi
    📸 Instagram: / brianferoldi
    📩 Newsletter: brianferoldi.com
    🕸️ Website: brianferoldi.com
    👨‍💼Brian Stoffel is a writer, investor, RUclipsr, and financial educator. He's a teacher at heart. Brian has been investing for over a decade and has written over 4,000 articles for The Motley Fool. Brian worked as a middle school teacher in Washington, DC for over 5 years. He and his wife had a “mini-retirement” in Costa Rica and now spent a portion of their year there in a containership home. Brian plans his life and his investments around “antifragile” principles.
    🤝Connect With Brian Stoffel:🤝
    🐦 Twitter: / brian_stoffel_
    📩 Newsletter: brianstoffel.com
    🕸️ Website: brianstoffel.com
    ❗️❗️DISCLAIMER:❗️❗️
    All content on this channel is for discussion, education, entertainment, and illustrative purposes only and SHOULD NOT be construed as professional financial advice, solicitation, or recommendation to buy or sell any securities, notwithstanding anything stated on this channel. There are risks associated with investing in securities. Loss of principal is possible. Past performance is not a predictor of future investment performance. Brian Feroldi and the guests on this channel are not responsible for investment actions taken by viewers. Should you need such advice, consult a licensed financial advisor, legal advisor, or tax advisor. You agree to verify all information yourself before investing. Any past performance discussed during this program is no guarantee of future results. Investing involves risk and possible loss of principal capital; please seek advice from a licensed professional.
    All views expressed are personal opinions as of the date of recording and are subject to change without the responsibility to update views. No guarantee is given regarding the accuracy of the information on this channel. Releasees undertake no obligation to provide accurate or sound investment statements. You waive any and all duties that may exist flowing from you to any Releasee. You agree not to hold any Releasee liable for any possible claim for damages arising from any decision you make based on information or other content on the Channel.
    *Some of the links and other products in this video are from companies for which Brian Feroldi will earn an affiliate commission or referral bonus. Brian Feroldi is part of an affiliate network and receives compensation for sending traffic to partner sites. The content in this video is accurate as of the posting date.

Комментарии • 39

  • @brettamerine5234
    @brettamerine5234 2 месяца назад +6

    thoughts on the glassdoor reviews?

    • @stoffelbrian
      @stoffelbrian 2 месяца назад +2

      They aren’t great. The company is scaling and addressing the OCS burnout. Wish it was better

  • @utkarshraj3399
    @utkarshraj3399 Месяц назад +1

    What do you think of XVIVO Perfusion from Sweden, who is progressing well in this space?

  • @platoscavealum902
    @platoscavealum902 Месяц назад

    Thank you.

  • @jackwilliamburgess
    @jackwilliamburgess 2 месяца назад +1

    Love the content, keep it up Brian. However, a few things you may have potentially overlooked on this analysis.
    The years until full year 2028 results is 4.75 instead of 4.1 (unless this was calculated a whilst back but on YE 2027 forecasts?). The current market cap with net debt is $2.9bill (not much impact). But the larger point, their recently 3 year avg dilution is 9.5% annually, and TTM was 10%. If we assumed only say 5% avg dilution over the next 5 years, on the basis they are hitting profitability, the share price return (instead of the market cap growth) is instead only circa 7%. You may obviously choose to use a lower avg dilution amount, but this impacts the return forecast

    • @stoffelbrian
      @stoffelbrian 2 месяца назад +1

      That's great color. I don't expect anywhere near the same level of dilution, but you're right to take that into account. FWIW, I fully expect them to hit 10,000 before the end of 2028, so it doesn't change the outcome *in this case*, but that is something to fix for future calculations. Thank you!

  • @zajunc69
    @zajunc69 2 месяца назад +1

    My bets on small caps are bill, pagaya technologies (alternative to upstart) and nervgen pharma (potential cure for spine cord injury)

  • @rogerfish9679
    @rogerfish9679 2 месяца назад +3

    Here's a dumb q: how do they make money? on each transplant? who pays?

  • @hansschmidt8292
    @hansschmidt8292 Месяц назад

    I agree that Transmedics is a great growth stock/company. I got in more than a year ago and then took profits before it was clear how the airline acquisition would affect profits. As soon as there was information on this I got in again and it is almost a 2 X for me since then. On the evaluation I think that taking Southwest as a business model results in underestimating their margins, a better way might be to check margins before and after the airline acquisition.

  • @koray6671
    @koray6671 2 месяца назад +7

    What percentage of transplants require long distance transport?

    • @petea625
      @petea625 2 месяца назад +2

      The point of the airline purchase was to be able to increase the radius of potential matches for OCS use. This, plus the significant increase in tissue survival time greatly increases the transplant radius for matches. The whole goal of Transmedics OCS is to increase transplant availability and efficacy. They are creating synergy with OCS plus air transportation. I have purchased and added since Feb 2020 DCA of $20. It may be pricey above $75 or so.

    • @jackwilliamburgess
      @jackwilliamburgess 2 месяца назад

      Allowing long distance expands the total number of transplants which can be made, so the % will likely increase versus the overall transplant volume over time. However, most of the current volume don't need very long distance jets (hence why they can be transplanted currently), so in my opinion TransMedic long range jets won't be cost effective options for the majority of transplants

    • @sirus312
      @sirus312 Месяц назад

      Look at the waitlist, it’s essentially all of them. Some can be on a waitlist for 5-7+ years depending on the organ if they get one at all

    • @josephcrivelli8477
      @josephcrivelli8477 Месяц назад +2

      TMDX seems like a great opportunity to invest in a company that fits well into a future you want to see!

  • @fabio2634
    @fabio2634 2 месяца назад

    I’m in

  • @BrettWordon
    @BrettWordon 2 месяца назад +1

    This makes me nervous, so much can go right..

  • @Turtytreeandaturd
    @Turtytreeandaturd 2 месяца назад

    My first question - how far along are they at in being able grow heart, lungs etc from stem cells?

    • @leweezo33
      @leweezo33 2 месяца назад

      good question but here is a follow up.. Will TMDX be used to transport those grown organs from lab to hospital?

    • @Turtytreeandaturd
      @Turtytreeandaturd 2 месяца назад

      @@leweezo33 wouldn't they possibly grow on site of the hospital? I don't know if they can grow or if possible..
      It is something that could be a future reality

    • @stoffelbrian
      @stoffelbrian 2 месяца назад +1

      @@Turtytreeandaturd I think that (while I hope for the possibility of such innovations) this is WAY into the future

    • @Turtytreeandaturd
      @Turtytreeandaturd 2 месяца назад

      @@stoffelbrian Thanks

    • @leweezo33
      @leweezo33 2 месяца назад

      @@Turtytreeandaturd I would think not just because you would have to spend huge on having a lab that grew and stored organs. I would think that having a few organ sites in stratgic parts of the country that could get organs to several hospitals quickly would be much better and easier.. I would be far more worried about them coming up with 3D printed robotic organs. But that is FAR away

  • @anthonycurrera3818
    @anthonycurrera3818 Месяц назад

    Does this company's stock have 10x potential?

  • @Mostly_bad
    @Mostly_bad Месяц назад

    I hate TAM analysis but love the company. Waiting for a better entry.

  • @sirus312
    @sirus312 Месяц назад

    A quick pushback on your southwest comparison. Wouldn’t it be best to compare to a private jet company. Many cite HIGH margins due to the fact their demand and cost are high. Same with organ transplant, the demand is constant/high. You don’t have EXTREME overhead like a public airline like Southwest which needs to cater to customers. The customers in this case can’t talk lol they just beat i the machine. So Private Jet companies have VERY high margins I believe.

    • @hansschmidt8292
      @hansschmidt8292 Месяц назад

      I agree. The real benefits of the airline acquisition are that they removed the bottle neck of available charter flights which results in an increased number of organs that can be used and that they save the money that would usually be the profit of thew charter flight company. A good way of looking at how the airline acquistion affected the profitability is to compare margins before and after the acquisition. They went down a bit but not as much as I would have thought. I don't remember the exact numbers but if I'm not mistaken gross margin decreased from around 70 to around 60%.

  • @markus0919
    @markus0919 2 месяца назад

    well 2028 is quite a long way from here but surely something to watch

  • @AveryFossen
    @AveryFossen Месяц назад +3

    Biggest lesson i learnt in 2023 in the stock market is that nobody knows what is going to happen next, so practice some humility and follow a strategy with a long term edge.

  • @cookarecoo
    @cookarecoo Месяц назад

    Great company, it will make organ harvesting a lot easier

  • @edtayag4696
    @edtayag4696 2 месяца назад +2

    Honestly looks like a good short. Lots of hypotheticals.

    • @edtayag4696
      @edtayag4696 2 месяца назад

      You have a better chance at better multiples investing in CHWY, WBD, or TOST with far less risk

    • @mattinterweb
      @mattinterweb Месяц назад

      Do hope you didn't!

  • @sociolocomtsac
    @sociolocomtsac Месяц назад

    Buying at 40 a share

  • @extramild1
    @extramild1 2 месяца назад +1

    Well, this smells nothing like Theranos does it?

    • @stoffelbrian
      @stoffelbrian 2 месяца назад +8

      No, it doesn’t. FDA approved. I’ve talked with doctors who use this. It isn’t a pre revenue company

    • @petea625
      @petea625 2 месяца назад +2

      I would suggest researching the Transmedics CEO. This nothing like Theranos.